Limelight Bio is a multi-platform, multi-disease biopharmaceutical company developing novel gene therapies. It has created proprietary technologies, advanced targets and drug candidates designed to overcome the limitations of current gene therapy and gene editing approaches. The company is focused on severe retinal, hematologic/metabolic, neurologic and hearing loss diseases where no current therapies exist.